Related references
Note: Only part of the references are listed.The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies
Constantin N. Baxevanis et al.
SEMINARS IN CANCER BIOLOGY (2021)
Causes of death after breast cancer diagnosis: A US population-based analysis
Ahmed M. Afifi et al.
CANCER (2020)
Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)
Agnes Dumas et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Ann Byrne et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Cytotoxic CD4+ T Cells in Bladder Cancer-A New License to Kill
Adrian G. Sacher et al.
CANCER CELL (2020)
TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity
Myrofora Panagi et al.
THERANOSTICS (2020)
Breast cancer prognosis signature: linking risk stratification to disease subtypes
Fulong Yu et al.
BRIEFINGS IN BIOINFORMATICS (2019)
A lymph node metastasis-related protein-coding genes combining with long noncoding RNA signature for breast cancer survival prediction
Yujie Sui et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Epigenome-wide association study for lifetime estrogen exposure identifies an epigenetic signature associated with breast cancer risk
Annelie Johansson et al.
CLINICAL EPIGENETICS (2019)
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
Y. -P. Chen et al.
ANNALS OF ONCOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Bruno Silva-Santos et al.
NATURE REVIEWS CANCER (2019)
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Michael J. Duffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
Zheng Xue et al.
CELL RESEARCH (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Hypertension: Focus on autoimmunity and oxidative stress
Heather Y. Small et al.
FREE RADICAL BIOLOGY AND MEDICINE (2018)
A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer
Christina M. Wilke et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
FOXP3 inhibits angiogenesis by downregulating VEGF in breast cancer
Xiaoju Li et al.
CELL DEATH & DISEASE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda et al.
GENOME RESEARCH (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells
Michiko Harao et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
Shany Koren et al.
MOLECULAR CELL (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Leisha A. Emens
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Subhra K. Biswas et al.
NATURE IMMUNOLOGY (2010)
Human Milk-Derived B Cells: A Highly Activated Switched Memory Cell Population Primed to Secrete Antibodies
Edouard Tuaillon et al.
JOURNAL OF IMMUNOLOGY (2009)
Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, of secondary CD8+ T cells and trafficking, and differentiation enhance tumor control
Melissa L. Hwang et al.
JOURNAL OF IMMUNOLOGY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Adjusting batch effects in microarray expression data using empirical Bayes methods
W. Evan Johnson et al.
BIOSTATISTICS (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
RL Camp et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
